ACE inhibitor suppresses cardiac remodeling after myocardial infarction by regulating dendritic cells and AT2 receptor-mediated mechanism in mice

Biomed Pharmacother. 2019 Jun:114:108660. doi: 10.1016/j.biopha.2019.108660. Epub 2019 Apr 8.

Abstract

Dendritic cells (DCs) play a complex role in the progression of myocardial infarction (MI). The impact of angiotensin-converting enzyme (ACE) inhibitor therapy, partly via affecting DCs maturation and recruitment, was tested on a MI mouse model. Furthermore, the cardioprotective effects of ACEI were enhanced through attenuating migration of DCs from the spleen into peripheral circulation, thereby inhibiting DCs maturation and tissue inflammation. ACEI repress DCs immune inflammatory response through down-regulating DCs maturation surface markers and regulating inflammatory cytokines, which led to a higher survival rate, improved function and remodeling through decreased inflammatory response after MI. However, inhibition of AT2R activation, resulted in a reduction of ACEI effects on DCs. The potent anti-inflammatory effect of ACEI can partially be attributed to its impact on DCs through activation of AT2R, which may provide a new target mechanism for ACEI therapy after MI.

Keywords: ACE inhibitor; AT(2) receptor; Dendritic cell; Inflammation; Myocardial infarction.

MeSH terms

  • Angiotensin Receptor Antagonists / pharmacology
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Dendritic Cells / drug effects*
  • Disease Models, Animal
  • Down-Regulation / drug effects
  • Heart / drug effects*
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / metabolism
  • Myocardium / metabolism
  • Receptor, Angiotensin, Type 2 / metabolism*
  • Survival Rate
  • Ventricular Remodeling / drug effects*

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Anti-Inflammatory Agents
  • Receptor, Angiotensin, Type 2